New Research Finds iCAD’s ProFound AI Risk for Digital Breast Tomosynthesis is 2.4x More Accurate Than Traditional Lifetime Risk Models

iCAD Inc publishes promising clinical research supporting ProFound AI Risk for Digital Breast Tomosynthesis in Science Translational Medicine.